Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

Now that Leg­end Biotech has se­cured its first ap­proval for the J&J-part­nered BC­MA CAR-T, it’s say­ing good­bye to its founder and CSO.

Frank Fan — who be­gan work­ing on the cell ther­a­py in 2014 when it was still housed in the Chi­nese CRO Gen­Script, took it to the in­ter­na­tion­al spot­light at 2017’s AS­CO con­fer­ence with stun­ning da­ta, ne­go­ti­at­ed a deal with J&J’s Janssen for it with $350 mil­lion up­front and steered it to an FDA OK days ago — re­signed from the com­pa­ny ef­fec­tive March 30, the com­pa­ny re­vealed Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER